Fair points. But Immutep has moved to a new phase so the market behavior will be different, imo. We no longer have to fear failed trial results.
Immutep’s prime asset has been de-risked by the “fast track” designation of the FDA. Particularly as they fast tracked it into 1st line head and neck treatment from its trial in second line. According to the seeking Alpha article this is very unusual.
Now I can read trial results from an educated layman’s point of view with interest in the topic and Tacti-002 looks great. But the FDA have the smartest people in the business running the rule over these trials. Efti is the goods.
With so many trials in the pipeline, positive Efti news is never far away. The only thing that can derail us is market volatility. So if you aren’t spooked by sudden falls precipitated by index volatility then it will be a great ride
- Forums
- ASX - By Stock
- GLOBAL LAG3 PURE PLAY
Fair points. But Immutep has moved to a new phase so the market...
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
32.0¢ |
Change
0.015(4.92%) |
Mkt cap ! $464.8M |
Open | High | Low | Value | Volume |
30.0¢ | 32.5¢ | 30.0¢ | $1.168M | 3.702M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 148547 | 32.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.5¢ | 51809 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 148547 | 0.320 |
3 | 107807 | 0.315 |
2 | 38192 | 0.310 |
2 | 58192 | 0.305 |
10 | 490669 | 0.300 |
Price($) | Vol. | No. |
---|---|---|
0.325 | 44309 | 1 |
0.330 | 179497 | 6 |
0.335 | 82304 | 5 |
0.340 | 49303 | 3 |
0.345 | 27527 | 3 |
Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online